Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $22.25 Consensus Target Price from Analysts

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has received an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $22.25.

A number of research firms recently commented on CAPR. Weiss Ratings restated a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Friday. Alliance Global Partners restated a “buy” rating on shares of Capricor Therapeutics in a research report on Monday, July 14th. Piper Sandler restated an “overweight” rating and set a $20.00 price target on shares of Capricor Therapeutics in a research report on Friday, July 11th. HC Wainwright restated a “buy” rating and set a $24.00 price target on shares of Capricor Therapeutics in a research report on Thursday, September 25th. Finally, Roth Capital decreased their price target on Capricor Therapeutics from $31.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, July 14th.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $6.20 on Wednesday. The firm has a market cap of $283.45 million, a PE ratio of -3.78 and a beta of 0.68. Capricor Therapeutics has a one year low of $5.68 and a one year high of $22.90. The stock’s 50 day simple moving average is $6.69 and its 200 day simple moving average is $8.71.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). As a group, equities analysts expect that Capricor Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new position in Capricor Therapeutics in the 3rd quarter valued at $28,000. Tower Research Capital LLC TRC boosted its position in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after buying an additional 4,976 shares during the last quarter. Citizens Financial Group Inc. RI bought a new position in Capricor Therapeutics in the 1st quarter valued at $95,000. Sheets Smith Investment Management bought a new position in Capricor Therapeutics in the 3rd quarter valued at $107,000. Finally, KLP Kapitalforvaltning AS boosted its position in Capricor Therapeutics by 65.2% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 4,300 shares during the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.